Loading
Life sciences · Journal article
Oncogenesis · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The 6th International Meeting “Metabolism and Cancer” was held at the Convention Center in La Grande Motte, France, on October 8–10, 2025. The three-day conference brought together 240 participants from eleven countries and featured 29 scientific presentations, including 15 invited lectures delivered by leading investigators in the field of oncometabolism. The program was structured into four thematic sessions: (i) diet, cachexia, microbiome, and microenvironment; (ii) stem cells and metabolic plasticity; (iii) epigenetics, epitranscriptomics, and metabolism; and (iv) metabolic control of drug resistance, therapy, and biomarkers. This meeting report highlights key conceptual advances and emerging directions discussed during the conference. Future progress in cancer metabolism will depend on elucidating the cross-talk between tumors and peripheral tissues, as organism-level metabolic regulation is likely to critically influence tumor growth, plasticity, and treatment sensitivity. Moving forward, a systems-level integration of metabolic, genomic, and spatial data is poised to redefine cancer metabolism from a descriptive field into a source of actionable vulnerabilities for precision oncology.